Identification and validation of prognostic proteomic biomarkers. (IMAGE)
Caption
(A) Workflow for selecting prognostic proteins, with candidate proteins represented as dots, annotated with their FC and hazard ratio (HR). (B, C) PRDX2 and DDX27 abundance in tumor tissues versus NATs was assessed using t-tests, while differences across proteomic subgroups were analyzed via ANOVA. Box plots display median values and interquartile ranges. (D, E) Kaplan-Meier survival curves for overall survival based on PRDX2 and DDX27 proteomic abundance (n = 159; solid lines), with P values from log-rank tests. (F) Immunohistochemical staining of PRDX2 in tumors and NATs. (G) PRDX2 expression levels in a validation cohort of 75 cases with gastric signet ring cell carcinoma. (H) Kaplan-Meier survival curves for overall survival based on PRDX2 immunostaining scores in the validation cohort (n = 75). (I) Immunohistochemical staining of DDX27 in tumors and NATs. (J) DDX27 expression levels in the validation cohort. (K) Kaplan-Meier survival curves for overall survival based on DDX27 immunostaining scores in the validation cohort (n = 75). *P < 0.05, **P < 0.01, and ***P < 0.001. PRDX2, peroxiredoxin 2; DDX27, DEAD-box helicase 27; NATs, normal adjacent tissues.
Credit
Zhiyuan Jin, Li Yuan, Yubo Ma, Zu Ye, Zhao Zhang, Yi Wang, Can Hu, Jinyun Dong, Xinuo Zhang, Zhiyuan Xu, Yian Du, Xiaoqing Guan, Guangzhao Pan, Sichao Tian, Juan Li, Ruiwen Zhang, Jiangjiang Qin, Xiangdong Cheng
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND